Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.69 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.56 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.56 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282359 | 1.00 | SCN9A (0.69) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2355930 | 0.92 | SCN9A (0.59) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL15314973 | 0.92 | SCN9A (0.59) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL12314671 | 0.86 | SCN9A (0.53) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL10289485 | 0.85 | SCN9A (0.51) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL280937 | 0.84 | SCN9A (0.86) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL19562310 | 0.84 | SCN9A (0.78) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL12314572 | 0.84 | SCN9A (0.48) | SCN9AGAATSHRMAPT | |
| SCHEMBL15314943 | 0.84 | SCN9A (0.48) | SCN9AGAATSHRMAPT | |
| SCHEMBL3326065 | 0.83 | SCN9A (0.50) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-03-09 | — | — | US | disclosed |
| US-9487535-B2 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-08 | — | — | US | disclosed |
| US-20130274483-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | PACIRA PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | OPRK1, OPRL1, PKD2 | SCN9A 51/4885SCN7A 29/4885SCN5A 22/4885 |
| US-20130274483-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | OPRK1, OPRL1, PKD2 | SCN9A 51/4885SCN7A 29/4885SCN5A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.